PD-217014

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C11H19NO2
Molecular Weight	197.2741
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@]1([H])C[C@@](CN)(CC(=O)OC)C2

InChI

InChIKey=ASBDKEXHKWHAPE-JZYVYDRUSA-N

InChI=1S/C11H19NO2/c1-14-10(13)6-11(7-12)4-8-2-3-9(8)5-11/h8-9H,2-7,12H2,1H3/t8-,9+,11+

HIDE SMILES / InChI

Molecular Formula	C11H19NO2
Molecular Weight	197.2741
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17989503 | https://clinicaltrials.gov/ct2/show/NCT00139672 | https://clinicaltrials.gov/ct2/show/NCT00139672 | https://adisinsight.springer.com/drugs/800021882

PD-217014 or PD-217,014, a new GABA analog was developed by Pfizer as a potent alpha(2)delta ligand of voltage-gated calcium channel, that and possessed visceral analgesic activity. This compound was undergoing phase II clinical trials for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). In addition, PD-217014 was investigated for postherpetic neuralgia treatment. However, all these studies were discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:06:44 UTC 2023` Edited by `admin` on `Sat Dec 16 02:06:44 UTC 2023`
Record UNII	K2T93E812G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PD-217014

Common Name

English

(±)-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID, 3-(AMINOMETHYL)-, METHYL ESTER, (1.ALPHA.,3.ALPHA.,5.ALPHA.)-

Common Name

English

(1.ALPHA.,3.ALPHA.,5.ALPHA.)-3-AMINOMETHYL-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID

Common Name

English

PD-217,014

Common Name

English

Code System Code Type Description

SMS_ID

300000041533